Tag: Pharmaceutical Innovation Award

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by World Science Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Published on by World Science Awards

Prof. Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Teharn University of Medical Sciences (TUMS), Iran

Prof. Ismaeil Haririan is a distinguished Professor of Pharmaceutics and Pharmaceutical Biomaterials at the Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), where he also serves as the Founder of the Department of Pharmaceutical Biomaterials and Head of the Biomaterials Research Center. He earned his Pharm.D. from Tabriz University and pursued a Ph.D. in Pharmaceutics at the University of London in 1993, followed by postdoctoral research in targeted drug delivery, which laid the foundation for his lifelong contributions to biomaterials and regenerative medicine. With over three decades of academic and research experience, Prof. Haririan has played a pioneering role in advancing interdisciplinary research that integrates pharmacy, materials science, and biomedical engineering. His research interests span the design of hyaluronic acid hydrogels for bone and cartilage regeneration, 3D pharming and bioprinting, microfluidics in pharmaceutical applications, drug delivery systems, nanomedicine, and pharmaceutical rheology. He has authored more than 120 SCI-indexed articles, earning over 3,600 citations, an h-index of 34, and an i10-index of 65, reflecting the global impact of his work. His research skills extend across tissue engineering, drug delivery system design, nanostructure characterization, and translational medicine, complemented by his strong expertise in mentoring doctoral candidates and industrial trainees. Recognized internationally as a leading figure in pharmaceutical biomaterials, Prof. Haririan has received numerous awards and honors, including recognition as a world leader in bioprinting research between 2022 and 2025. Beyond his scholarly contributions, he has served in editorial capacities, led major research collaborations, and advanced education by supervising Pharm.D. and Ph.D. students. In conclusion, Prof. Haririan embodies academic excellence, visionary leadership, and innovative research, making him one of the most influential scientists in pharmaceutics and biomaterials whose work continues to inspire progress in regenerative medicine and pharmaceutical sciences worldwide.

Profile: Scopus | ORCID

Featured Publications

Al-Jawadri, A. M. H., Karami, Z., Haririan, I., Akrami, M., & Gholami, M. (2025). Development of a bio-inspired phagocytic stable nanoghost with anti-inflammatory properties for management of inflammation in ulcerative colitis. Journal of Drug Targeting, 33(7), 1-15.

Safari, F., Goudarzi, A., Abolghasemi, H., Mohammad, H. A., Akrami, M., Mohammadi, S., & Haririan, I. (2025). Additive manufacturing of regorafenib tablets: Formulation strategies and characterization for colorectal cancer. Polymers, 17(17), 2302.

Sohrabi, R., Miri, A. H., Rad-Malekshahi, M., Saadatpour, F., Pourjabbar, B., Keshel, S. H., Arefian, E., Balalaei, S., Masoumi, A., Khalili, F., Haririan, I., Akrami, M., & Shahriari, M. H. (2025). Corrigendum to “Development of silk fibroin/collagen film containing GI-20 peptide-loaded PLGA nanoparticles against corneal herpes simplex virus-1” [International Journal of Pharmaceutics, 669 (2025), 125022]. International Journal of Pharmaceutics, 674, 125369.

Torabi, M., Haririan, I., Foroumadi, A., Ghanbari, H., & Ghasemi, F. (2024). A deep learning model based on the BERT pre-trained model to predict the antiproliferative activity of anti-cancer chemical compounds. SAR and QSAR in Environmental Research, 35(11), 971-992

Sa Xiao | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Sa Xiao | Pharmaceutical Science | Best Researcher Award

Chief Pharmacist, Clinical pharmacist from The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, China

Sa Xiao is an experienced Clinical Pharmacist currently working at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China. she has dedicated her career to clinical pharmacy with a focus on providing quality patient care and optimizing pharmaceutical practices. Sa Xiao holds a Master’s degree in Pharmacology and a Bachelor’s degree in Pharmaceutical Engineering. Over the past five years and seven months, she has consistently contributed to clinical pharmacy, focusing on improving therapeutic outcomes and pharmaceutical interventions. Sa Xiao’s role places her at the intersection of clinical application and pharmaceutical research, where she works to enhance drug therapy effectiveness and patient safety. Her work contributes directly to hospital-based pharmaceutical care and supports interdisciplinary collaboration in medical settings. Sa Xiao’s background equips her with both theoretical knowledge and practical clinical experience, positioning her as a valuable asset in the healthcare system. While her current profile emphasizes her clinical expertise, expanding her research portfolio could further elevate her impact in the pharmaceutical field. Her dedication, professional growth, and potential for further research contributions make her a promising candidate for recognition in her domain.

Professional Profile

Education

Sa Xiao has built a strong academic foundation that supports her professional excellence in clinical pharmacy. She began her higher education journey at Huzhou Normal University, where she pursued a Bachelor’s degree in Pharmaceutical Engineering from September 2012 to June 2016. This program provided her with essential knowledge of pharmaceutical sciences, drug formulation, and pharmaceutical manufacturing processes. Her education at this stage focused on understanding drug properties, production, and the basic principles that guide pharmaceutical development. After completing her undergraduate studies, Sa Xiao advanced her academic qualifications by enrolling in Guangdong Medical University, where she earned her Master’s degree in Pharmacology from September 2016 to June 2019. This graduate program allowed her to delve deeper into the study of drug actions, mechanisms, and pharmacokinetics. Through her Master’s studies, she developed a comprehensive understanding of clinical pharmacology, which now directly supports her work as a clinical pharmacist. Both her degrees are recognized by the Ministry of Education, China, affirming the academic rigor and credibility of her educational background. Her academic journey demonstrates a seamless transition from pharmaceutical engineering to clinical application, providing her with the necessary expertise to excel in both pharmaceutical sciences and patient-centered clinical practice.

Professional Experience

Sa Xiao has gained substantial professional experience as a Clinical Pharmacist, holding this role since July 2019 at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. With over five years of experience, she has developed a deep understanding of clinical pharmacy operations, patient care protocols, and hospital pharmaceutical services. Her responsibilities likely include reviewing prescriptions, optimizing medication therapies, ensuring the safe and effective use of drugs, and collaborating with medical teams to enhance patient outcomes. Working in a hospital affiliated with a reputable university has provided her with exposure to clinical research, medical education, and interdisciplinary cooperation. Sa Xiao’s experience is not limited to routine pharmacy tasks; her role also requires ongoing learning and adaptation to the latest pharmaceutical guidelines and therapeutic advancements. Her career has been characterized by dedication to improving patient care and supporting evidence-based clinical decisions. While her profile currently focuses on clinical responsibilities, there is potential for her to expand her contributions to include scientific publications, research studies, and leadership in pharmaceutical innovations. Her professional track record reflects commitment, consistency, and the ability to thrive in a demanding healthcare environment.

Research Interest

Sa Xiao’s research interests are rooted in clinical pharmacy and pharmacology, with a focus on optimizing drug therapies, enhancing patient safety, and improving pharmaceutical care within hospital settings. Her academic and professional background suggests a strong interest in therapeutic drug monitoring, drug interactions, and evidence-based medication management. She is likely driven to explore methods for improving the clinical efficacy of pharmacological treatments and minimizing adverse drug reactions. Additionally, she may be interested in research concerning personalized medicine, dosage adjustments for specific patient populations, and clinical outcomes related to pharmaceutical interventions. Her experience as a clinical pharmacist positions her to contribute valuable insights into hospital-based drug management, prescription review processes, and the practical challenges faced in clinical settings. Future research could also include comparative studies on the effectiveness of different pharmacological treatments and the implementation of clinical pharmacy protocols to improve patient care. By aligning her clinical expertise with focused research initiatives, Sa Xiao has the potential to contribute to both national and international discussions in the field of clinical pharmacology and pharmacy practice. Expanding her research interests to cover these areas would significantly strengthen her academic and professional profile.

Research Skills

Sa Xiao possesses a range of research skills that align with her clinical pharmacy background. Her academic training in pharmacology provided her with expertise in drug action mechanisms, pharmacokinetics, and pharmacodynamics, which are essential for conducting clinical pharmaceutical research. She likely has experience in analyzing clinical data, reviewing case studies, and evaluating therapeutic outcomes in real-world settings. Her role as a clinical pharmacist has refined her skills in prescription auditing, patient counseling, and drug therapy evaluation, which contribute to her ability to design practical, patient-focused research projects. Sa Xiao is also expected to be proficient in using clinical databases, medical literature review systems, and pharmacovigilance tools to support her clinical decision-making and potential research activities. Moreover, she may have developed collaborative skills through working with interdisciplinary teams, which are critical for conducting joint clinical studies and implementing hospital-wide pharmaceutical protocols. To further enhance her research portfolio, acquiring advanced skills in statistical analysis, research methodology, and scientific writing would be beneficial. By building on her current skill set and actively participating in research dissemination through conferences and publications, Sa Xiao can establish herself as a leading contributor in the clinical pharmacy research community.

Awards and Honors

At present, no specific awards or honors have been provided for Sa Xiao. However, her sustained commitment to clinical pharmacy over a period of more than five years at a leading university hospital reflects her professional reliability and growing expertise. Although formal recognitions such as research awards, clinical excellence distinctions, or academic honors have not yet been documented, Sa Xiao’s continuous role in a competitive healthcare environment signifies institutional trust in her capabilities. It is possible that she has received internal recognition for her contributions to patient care, medication management, or quality improvement initiatives within her department. Engaging in national or international pharmaceutical competitions, participating in recognized clinical research projects, and contributing to peer-reviewed publications could open avenues for future awards and honors. Earning formal recognition would not only validate her contributions but also help strengthen her professional profile for broader scientific and clinical acknowledgment. Sa Xiao’s consistent career growth and practical impact within the hospital setting suggest that she is well-positioned to achieve significant honors as she continues to expand her involvement in clinical research and professional development activities in the future.

Conclusion

In conclusion, Sa Xiao is a highly capable clinical pharmacist with a strong educational background and valuable experience in the hospital pharmaceutical sector. Her work at The Sixth Affiliated Hospital, School of Medicine, South China University of Technology demonstrates her ability to apply pharmacological knowledge in a clinical environment, directly benefiting patient care and therapeutic practices. While her current profile is predominantly clinical, there is significant potential for her to make substantial research contributions to the field of clinical pharmacy and pharmacology. Sa Xiao’s foundation in pharmaceutical engineering and pharmacology equips her with both theoretical and practical expertise, which can be further advanced through scientific publications, conference presentations, and research collaborations. By actively participating in research dissemination and seeking broader recognition through professional awards, she can enhance her influence within the scientific and medical communities. Sa Xiao’s dedication, clinical precision, and future research potential position her as an emerging contributor to the advancement of pharmaceutical care and clinical pharmacy research. With further academic engagement and research output, she is likely to achieve greater professional recognition and make impactful contributions to the global healthcare landscape.

Publications Top Notes

1. Depression and Suicide/Self-Injury Signals for Weight Loss Medications: A Disproportionality Analysis of Semaglutide, Liraglutide, and Tirzepatide in FAERS Database

  • Journal: Journal of Affective Disorders

  • Publication Date: 2025-06-14

  • Authors: Wang M, Yang Z, Yan M, Liu S, Xiao S

2. Protective Effects of Aqueous Extract of Wampee Fruit Against Anti-Tubercular Drug-Induced Hepatotoxicity in Rats

  • Journal: Journal of Biological Regulators and Homeostatic Agents

  • Publication Date: 2019-01-01

  • Authors: Guan TM, Xiao S, Liu DC, Liao XH, Li WD, Wu KF, Huang R

 

Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Published on by World Science Awards

Assist. Prof. Dr. Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Faculty Member from Neyshabur university of medical sciences, Iran

Dr. Amir Abbas Momtazi-Borojeni is an Assistant Professor of Medical Biotechnology at Neyshabur University of Medical Sciences in Iran. Born on September 17, 1985, in Isfahan, Iran, he has established a distinguished career in medical biotechnology, focusing on nanomedicine, immunotherapy, and phytomedicine. With over 160 publications and more than 7,000 citations, his research has significantly contributed to the fields of cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies and nanoliposomal drug delivery systems has been recognized internationally. Dr. Momtazi-Borojeni’s interdisciplinary approach integrates molecular biology, pharmacology, and bioinformatics, reflecting his commitment to advancing medical science through innovative research.

Professional Profile​

Education

Dr. Momtazi-Borojeni’s academic journey began with a BSc in Biology from Isfahan University (2004–2008), followed by an MSc in Microbial Biotechnology from the same institution (2008–2010). He then pursued a Ph.D. in Medical Biotechnology at Mashhad University of Medical Sciences (2013–2019), where his research focused on developing nanoliposome-based vaccines targeting PCSK9 for lipid-lowering and anti-atherosclerotic effects. His doctoral work combined immunology, nanotechnology, and cardiovascular research, laying the foundation for his future contributions to medical biotechnology.​

Professional Experience

Dr. Momtazi-Borojeni has held various research and academic positions, including roles as a genomics lab expert at the Biotechnology Research Institute in Esfahan and as a part-time researcher at the Pharmaceutical Sciences Research Center of Isfahan University of Medical Sciences. He has also taught courses in cellular and molecular biology, genetic engineering, and bioinformatics at Isfahan University and Islamic Azad University, Neyshabur branch. Currently, he serves as an Assistant Professor at Neyshabur University of Medical Sciences, where he continues to advance research in medical biotechnology.​

Research Interests

Dr. Momtazi-Borojeni’s research interests encompass nanomedicine, immunotherapy, and phytomedicine, with a particular focus on developing innovative treatments for cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies, including vaccine development and siRNA delivery systems, aims to provide alternative strategies for managing hypercholesterolemia and atherosclerosis. Additionally, he explores the therapeutic potential of natural compounds and bioinformatics approaches to identify novel drug targets and understand disease mechanisms.​

Research Skills

Dr. Momtazi-Borojeni possesses a diverse skill set that includes expertise in nanotechnology-based drug delivery, molecular biology techniques, immunological assays, and bioinformatics analysis. His proficiency in designing and characterizing nanoliposomes, conducting in vivo studies, and analyzing gene expression profiles enables him to undertake complex research projects that bridge multiple disciplines. His collaborative work with international researchers further demonstrates his ability to contribute to multidisciplinary teams and advance scientific knowledge.​

Awards and Honors

While specific awards and honors are not detailed in the provided information, Dr. Momtazi-Borojeni’s extensive publication record and citation metrics reflect his significant impact on the field of medical biotechnology. His research has been published in reputable journals, and his contributions to the development of PCSK9-targeted therapies have garnered international recognition. His active participation in scientific communities and collaborations with researchers worldwide underscore his commitment to advancing medical science.​

Conclusion

Dr. Amir Abbas Momtazi-Borojeni’s extensive research in medical biotechnology, particularly in the areas of nanomedicine and immunotherapy, positions him as a strong candidate for the Best Researcher Award. His innovative approaches to treating cardiovascular and metabolic diseases, combined with his interdisciplinary expertise and collaborative spirit, have significantly advanced the field. While specific awards and honors are not listed, his prolific publication record and international collaborations attest to his contributions to medical science. Continued support for his research endeavors will likely yield further breakthroughs in therapeutic strategies and enhance our understanding of complex diseases.​

Publications Top Notes

  1. Therapeutic effects of curcumin in inflammatory and immune‐mediated diseases: A nature‐made jack‐of‐all‐trades?

    • Authors: E. Abdollahi, A.A. Momtazi, T.P. Johnston, A. Sahebkar

    • Year: 2018

    • Citations: 302

  2. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled trial

    • Authors: Y. Panahi, N. Khalili, E. Sahebi, S. Namazi, L.E. Simental-Mendía, M. Majeed, A. Sahebkar

    • Year: 2018

    • Citations: 257

  3. Curcumin as a MicroRNA regulator in cancer: a review

    • Authors: A.A. Momtazi, F. Shahabipour, S. Khatibi, T.P. Johnston, M. Pirro, A. Sahebkar

    • Year: 2016

    • Citations: 256

  4. Curcumin: A natural modulator of immune cells in systemic lupus erythematosus

    • Authors: A.A. Momtazi-Borojeni, S.M. Haftcheshmeh, S.A. Esmaeili, T.P. Johnston, A. Sahebkar

    • Year: 2018

    • Citations: 233

  5. Isolation, identification, and characterization of cancer stem cells: A review

    • Authors: M.R. Abbaszadegan, V. Bagheri, M.S. Razavi, A.A. Momtazi, A. Sahebkar

    • Year: 2017

    • Citations: 228

  6. Curcumin: a potentially powerful tool to reverse cisplatin-induced toxicity

    • Authors: R. Rezaee, A.A. Momtazi, A. Monemi, A. Sahebkar

    • Year: 2017

    • Citations: 199

  7. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease

    • Authors: A.S. Moghaddam, J.T. Afshari, S.A. Esmaeili, E. Saburi, Z. Joneidi, A. Sahebkar

    • Year: 2019

    • Citations: 196

  8. A review on the pharmacology and toxicology of steviol glycosides extracted from Stevia rebaudiana

    • Authors: A. Abbas Momtazi-Borojeni, S.A. Esmaeili, E. Abdollahi, A. Sahebkar

    • Year: 2017

    • Citations: 192

  9. Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases

    • Authors: A.A. Momtazi, G. Derosa, P. Maffioli, M. Banach, A. Sahebkar

    • Year: 2016

    • Citations: 186

  10. Difluorinated curcumin: A promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile

    • Authors: A. Abbas Momtazi, A. Sahebkar

    • Year: 2016

    • Citations: 178

Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Published on by World Science Awards

Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Associate Professor from Department of Physiology, China Medical University, Taiwan

Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.

Professional Profile

Education

Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.

Professional Experience

Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.

Research Interests

Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.

Research Skills

Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.

Awards and Honors

Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.

Conclusion

Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.

Publication Top Notes

M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025

2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025

3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025

4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024

5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024

6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2

7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2

Niclas Nikolai Stephanson | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Mr. Niclas Nikolai Stephanson | Pharmaceutical Science | Best Researcher Award

Scientist from Karolinska University Hospital, Sweden

Niclas Nikolai Stephanson is a seasoned clinical pharmacologist and forensic chemist based at the Karolinska University Hospital in Stockholm, Sweden. With a career spanning over three decades, he has carved out a notable reputation in the scientific community, particularly in the analysis of drugs of abuse. Holding a PhD in Medicine from the prestigious Karolinska Institutet, he combines academic rigor with practical experience. Niclas is a licensed pharmacist, senior chemist, and prolific researcher whose contributions include over 35 peer-reviewed scientific publications. His research focus lies at the intersection of pharmacology and toxicology, with a specialization in mass spectrometry and method development for detecting drugs in biological materials. He plays a pivotal role in improving clinical and forensic diagnostics through enhanced analytical techniques. Niclas’s work has contributed to better accuracy in detecting and quantifying illicit and therapeutic drugs, ultimately supporting public health and justice systems. His long-standing association with one of Europe’s most reputable hospitals is a testament to his dedication, expertise, and continuous contribution to the advancement of clinical pharmacology. Stephanson stands out not only for his technical skills but also for his impactful research that bridges laboratory science with real-world applications in healthcare and law enforcement.

Professional Profile

Education

Niclas Nikolai Stephanson received his academic training at the renowned Karolinska Institutet in Stockholm, Sweden, where he earned his PhD in Medicine in 2007. His doctoral work was rooted in the Department of Medicine and focused on the interdisciplinary field of clinical pharmacology, an area combining pharmacokinetics, pharmacodynamics, and toxicology. Prior to his doctoral studies, Niclas qualified as a licensed pharmacist, which provided him with a strong foundation in pharmaceutical sciences, drug interactions, and patient-centered pharmacotherapy. His dual academic background in pharmacy and medicine positions him at the nexus of research and clinical practice. This educational pathway has enabled him to integrate principles of chemistry, biology, and medicine in his professional work. Niclas’s academic experience at Karolinska Institutet—a globally respected institution known for its role in awarding the Nobel Prize in Physiology or Medicine—further highlights the high standards and intellectual rigor of his training. The comprehensive and multidisciplinary nature of his education has empowered him to design and conduct advanced analytical research while maintaining a deep understanding of clinical implications. Overall, his educational background has significantly influenced his ability to carry out complex method development and toxicological investigations with precision and clinical relevance.

Professional Experience

Niclas Nikolai Stephanson has been professionally affiliated with Karolinska University Hospital in Stockholm since August 1992, where he currently holds the position of Senior Chemist in the Department of Clinical Pharmacology. Over the span of more than three decades, he has contributed significantly to the hospital’s mission of delivering cutting-edge clinical diagnostics and therapeutic monitoring. As a licensed pharmacist and senior forensic chemist, Niclas has specialized in the analysis of drugs of abuse, playing a key role in the development and implementation of advanced analytical techniques for routine and investigational use. His daily responsibilities involve overseeing laboratory operations, mentoring junior staff, and collaborating with clinicians to interpret toxicological results. His long tenure reflects not only technical proficiency but also institutional trust in his expertise and leadership. Working within a hospital setting, he has consistently ensured that his research aligns with real-world clinical demands, particularly in the identification and quantification of illicit substances and medications in complex biological matrices. Stephanson’s role at Karolinska University Hospital also supports legal and forensic proceedings, as accurate drug analysis is crucial for both medical and judicial outcomes. His professional experience highlights a unique blend of scientific inquiry, clinical application, and public health impact.

Research Interests

Niclas Nikolai Stephanson’s research interests are centered on clinical pharmacology, forensic toxicology, and analytical chemistry, with a particular focus on the detection and analysis of drugs of abuse. He is especially committed to method development in toxicological screening, applying advanced techniques such as mass spectrometry to improve the precision and sensitivity of drug detection. His work often explores various biological matrices—ranging from blood and urine to less conventional materials like hair or oral fluid—to assess the presence and metabolism of illicit and therapeutic substances. Niclas’s interest in mass spectrometry enables the high-resolution identification of complex compounds, which is critical for timely and accurate diagnoses in both clinical and forensic settings. He is also interested in validating new protocols for routine use in healthcare facilities, aiming to bridge the gap between research and clinical practice. Additionally, his work contributes to public safety by improving methodologies used in legal and judicial drug testing. Through collaborations and internal projects at Karolinska University Hospital, his research continues to evolve in response to emerging substances and new analytical challenges. Overall, his interests reflect a strong alignment with societal needs in healthcare and law enforcement, emphasizing both scientific innovation and practical application.

Research Skills

Niclas Nikolai Stephanson possesses a robust set of research skills that underscore his success as a senior clinical chemist and academic contributor. One of his core strengths lies in advanced method development, particularly in the field of forensic toxicology, where he designs, tests, and refines techniques for detecting drugs of abuse in biological matrices. His proficiency in mass spectrometry—including LC-MS/MS and GC-MS systems—is central to his work, enabling precise identification and quantification of substances even in trace amounts. Niclas is also skilled in biological sample preparation, including extraction and purification techniques that are critical for ensuring reliable analytical results. He demonstrates strong data analysis and validation abilities, ensuring that his methods meet rigorous standards for reproducibility, sensitivity, and specificity. In addition, he has experience in regulatory compliance and quality assurance, ensuring that laboratory practices align with healthcare and forensic standards. His skill set extends to scientific writing and publication, as evidenced by his record of more than 35 peer-reviewed articles. These competencies, combined with his practical knowledge of clinical workflows, empower him to translate complex research into diagnostic and therapeutic tools. His research skills are not only technical but also strategic, aiming to meet real-world challenges with innovative scientific solutions.

Awards and Honors

Although specific awards or honors for Niclas Nikolai Stephanson are not explicitly listed, his sustained position at Karolinska University Hospital and the volume of his peer-reviewed publications are indicative of high professional recognition and esteem. Holding a senior chemist position at one of Europe’s leading medical institutions is a reflection of both his expertise and institutional trust in his abilities. His role in the department of Clinical Pharmacology implies consistent recognition through internal appointments, research responsibilities, and possibly departmental accolades for contributions to method development and toxicological analysis. Publishing over 35 scientific articles in peer-reviewed journals also suggests peer recognition and validation of his work within the scientific community. It is not uncommon in the medical sciences for researchers with such a track record to be involved in national and international working groups or to serve as peer reviewers or advisors in forensic and clinical pharmacology. His continued association with the Karolinska Institutet—home to Nobel-level research—implies a professional standing that exceeds routine recognition. While specific honors may not be documented publicly, his contributions and career longevity highlight a professional trajectory marked by consistent achievement and expert-level contribution to clinical science.

Conclusion

Niclas Nikolai Stephanson stands as a highly accomplished clinical pharmacologist and forensic chemist whose contributions span research, diagnostics, and public health. His work at Karolinska University Hospital since 1992, combined with a PhD from Karolinska Institutet, demonstrates a career dedicated to scientific excellence and societal impact. He has specialized in the development of analytical methods using mass spectrometry to detect drugs of abuse, contributing to over 35 peer-reviewed publications. His research not only enhances clinical decision-making but also supports forensic and legal systems by ensuring accurate and timely drug testing. While his achievements are impressive, expanding his international collaborations and diversifying his research themes could further amplify his academic influence. Nonetheless, his sustained excellence and deep specialization in clinical pharmacology make him a valuable asset to the scientific and medical community. Stephanson’s profile exemplifies the rare blend of research depth, clinical utility, and long-term dedication, positioning him as a strong candidate for prestigious honors such as the Best Researcher Award. His work bridges the gap between bench science and bedside application, marking him as a leader in toxicological innovation and a model for aspiring researchers in the field.

Publications Top Notes

  1. Title: Application of liquid chromatography combined with high resolution mass spectrometry for urine drug testing
    Authors: O.M.L. Beck (Olof M.L.), A. Rylski (Alexia), N.N. Stephanson (Nikolai N.)
    Citations: 4

  2. Title: Use of LC–HRMS in full scan-XIC mode for multi-analyte urine drug testing – a step towards a ‘black-box’ solution?
    Authors: N.N. Stephanson (Nikolai N.), P. Signell (Patrick), A. Helander (Anders), O.M.L. Beck (Olof M.L.)
    Year: 2017
    Citations: 19

Rohidas Arote | Pharmaceutical Science | Biotechnology Advancement Award

Published on by World Science Awards

Prof. Rohidas Arote | Pharmaceutical Science | Biotechnology Advancement Award

Dr. Rohidas B. Arote is a distinguished professor in the Center for Nano and Material Sciences at Jain University, Bangalore, India. With over two decades of experience in biotechnology, gene therapy, and drug delivery, he has made substantial contributions to biomedical research. His expertise lies in biomaterials, pharmacology, toxicology, and theranostics, particularly in cancer, immune, and regenerative therapies. Having served as a professor at Seoul National University (SNU), a globally ranked institution, he has led groundbreaking research in non-viral gene delivery systems and targeted drug delivery for cancer therapy. Dr. Arote has secured major research grants, collaborated with international institutions, and delivered invited talks at global conferences. He has received prestigious awards such as the Creative Pioneering Research Award and IAAM Scientist Medal. In addition to his academic achievements, he actively contributes to international scientific societies, reviews for high-impact journals, and organizes leading scientific conferences. With a strong track record of publications, research funding, and innovation, Dr. Arote continues to be a key figure in biomedical and pharmaceutical sciences, advancing cutting-edge solutions for healthcare and drug development.

Professional Profile

Education

Dr. Rohidas B. Arote holds a Ph.D. in Biotechnology (2009) from Seoul National University, South Korea, where he specialized in gene therapy and drug delivery systems. His doctoral research focused on developing non-viral polymeric gene carriers for targeted cancer therapy. Before pursuing his Ph.D., he earned a Master of Science (M.S.) in Pharmacognosy and Phytochemistry (2002) from the University of Mumbai, India, where he gained expertise in natural product chemistry and pharmaceutical formulations. His academic journey began with a Bachelor of Science (B.S.) in Pharmaceutical Sciences (2000) from the University of Pune, India, equipping him with a strong foundation in pharmaceutics, drug formulation, and biotechnology. Throughout his education, he has been a recipient of several prestigious fellowships, including the Brain Korea (BK21) Fellowship (2008) and the Korea Science and Engineering Fellowship (KOSEF) (2005). He was also a GATE Scholar in Pharmacy (2000), a competitive national-level qualification exam conducted by IIT Kharagpur, India. His interdisciplinary academic background, spanning biotechnology, pharmaceutical sciences, and biomedical engineering, has enabled him to develop innovative solutions in gene therapy, biomaterials, and targeted drug delivery.

Professional Experience

Dr. Rohidas B. Arote has over 20 years of academic and research experience across prestigious institutions worldwide. He is currently a Professor at the Center for Nano and Material Sciences, Jain University, Bangalore (2021-present), where he leads cutting-edge research in nanomedicine and biomaterials. Prior to this, he served at Seoul National University (SNU), South Korea, as an Associate Professor (2017-2020) and Assistant Professor (2010-2017), where he developed gene delivery technologies for cancer therapy. He also worked as a Research Associate (2009-2010) at SNU, focusing on polymeric carriers for gene therapy. In addition, he held visiting professor positions at King Abdullah University of Science and Technology (KAUST), Saudi Arabia (2019-2020), and the Indian Institute of Science (IISc), Bangalore (2019-2020), contributing to advanced biomedical research. Early in his career, he gained industry experience as a Formulation & Development Scientist at Ajanta Pharma Ltd, Mumbai (2003-2004). His diverse academic, research, and industry experience has made him a leader in drug delivery, biomaterials, and biomedical engineering.

Research Interests

Dr. Rohidas B. Arote’s research focuses on gene therapy, drug delivery, biomaterials, biomedical engineering, pharmacology, toxicology, and theranostics. He is particularly interested in developing novel non-viral gene delivery systems for targeted cancer therapy. His work involves designing biodegradable polymeric nanocarriers for effective gene transfection, with applications in cancer, immune, and regenerative therapies. He explores nanotechnology-based drug delivery to enhance the bioavailability and therapeutic efficacy of pharmaceuticals. Additionally, he investigates biocompatible materials for tissue engineering and regenerative medicine, contributing to the development of next-generation biomaterials for medical applications. His interdisciplinary research bridges biotechnology, materials science, and pharmaceutical sciences, addressing critical challenges in disease treatment and drug delivery. Through collaborations with global research institutions, he continues to push the boundaries of biomedical research by integrating nanomedicine, molecular biology, and bioengineering to develop innovative therapeutic strategies.

Research Skills

Dr. Rohidas B. Arote possesses a diverse set of advanced research skills in biomedical and pharmaceutical sciences. He is an expert in nanotechnology-based drug delivery, specializing in the synthesis and characterization of biodegradable polymers for gene therapy applications. He has expertise in molecular biology techniques, including gene cloning, siRNA delivery, and CRISPR-based genome editing. His skills extend to polymeric biomaterials design, nanoparticle synthesis, and surface modification for targeted drug delivery. He is proficient in in vitro and in vivo models for evaluating gene expression, drug efficacy, and toxicity in preclinical studies. Additionally, he has experience in high-throughput screening, bioinformatics, and computational modeling for drug formulation optimization. His research involves the development of multifunctional polymeric carriers, receptor-mediated drug targeting, and biodegradable materials for regenerative medicine. His strong analytical and problem-solving abilities have enabled him to successfully secure research funding, publish in top-tier scientific journals, and contribute to cutting-edge biomedical innovations.

Awards and Honors

Dr. Rohidas B. Arote has received numerous prestigious awards for his pioneering research in gene therapy and biomaterials. He was honored with the Creative Pioneering Research Award (2017) from Seoul National University, recognizing his innovative contributions to biomedical research. He also received the IAAM Scientist Medal (2017) from the International Association of Advanced Materials, highlighting his excellence in advanced materials and nanomedicine. Other notable accolades include the Research Excellence Award (2010) from the Research Institute for Agriculture and Life Sciences and the Young Scientist Award (2008) from the 16th POLYCHAR: World Forum on Advanced Materials. He has been a Brain Korea (BK21) Fellow (2008) and received the Korea Science and Engineering Fellowship (KOSEF) (2005). His early academic achievements include being a GATE Scholar in Pharmacy (2000), a highly competitive national-level distinction. These awards reflect his outstanding research contributions, leadership in academia, and dedication to advancing biomedical sciences.

Conclusion

Dr. Rohidas B. Arote is an exceptional researcher and academic leader with a remarkable career spanning over two decades in biotechnology, gene therapy, and drug delivery. His contributions in biomaterials, nanomedicine, and regenerative therapies have significantly advanced the field of biomedical sciences. Through his research, funding acquisitions, and scientific collaborations, he has played a crucial role in developing novel drug delivery systems for cancer therapy. His achievements in securing high-impact publications, international awards, and research grants showcase his dedication to scientific excellence. In addition to his research, he has contributed as a peer reviewer, conference organizer, and mentor, shaping the next generation of biomedical researchers. As a professor at Jain University, Bangalore, and a former faculty member at Seoul National University, he continues to lead groundbreaking research in nanomedicine. With his strong academic background, innovative research, and global scientific impact, Dr. Arote stands as a deserving candidate for prestigious research awards, making a lasting impact in healthcare and pharmaceutical sciences.

Publications Top Notes

  1. Title: Microfluidics in Bioanalytical Chemistry
    Authors: R. Nisarga, P.P. Pandit, J.N. Sangshetti, R.B. Arote
    Year: Not provided

  2. Title: Exploring Antibiofilm Potential of Some New Imidazole Analogs Against C. Albicans: Synthesis, Antifungal Activity, Molecular Docking and Molecular Dynamics Studies
    Authors: S.K. Pathan, A.V. Shelar, S.U. Deshmukh, R.H. Patil, J.N. Sangshetti
    Year: 2023
    Citations: 1

  3. Title: In Silico Structure-Based Drug Design Approach to Find Potential Hits in Ventilator-Associated Pneumonia Caused by Pseudomonas aeruginosa
    Authors: M.G. Damale, R.B. Patil, S.A. Ansari, R.B. Arote, J.N. Sangshetti
    Year: 2022
    Citations: 2

  4. Title: Efficient Gene Transfection to Lung Cancer Cells via Folate-PEI-Sorbitol Gene Transporter
    Authors: K. Cho, S. Kim, H. Chun, A. Lee, R.B. Arote
    Year: 2022
    Citations: 6

  5. Title: Development of Novel, Biocompatible, Polyester Amines for Microglia-Targeting Gene Delivery
    Authors: B. Choi, M. Ahn, S. Hong, R.B. Arote, S.J. Lee
    Year: 2021
    Citations: 1

  6. Title: Insights of Tankyrases: A Novel Target for Drug Discovery
    Authors: M.G. Damale, S.K. Pathan, D.B. Shinde, R.B. Arote, J.N. Sangshetti
    Year: 2020
    Citations: 26

  7. Title: Boric Acid: A Versatile Catalyst in Organic Synthesis
    Authors: S.K. Pathan, P.R. Mahaparale, S.U. Deshmukh, R.B. Arote, J.N. Sangshetti
    Year: Not provided
    Citations: 5

Suyu Liu | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Suyu Liu | Pharmaceutical Science | Best Researcher Award

Associate Professor at MD Anderson Cancer Center, United States

Dr. Suyu Liu is a distinguished researcher and academic in the field of [specific expertise]. With a strong background in [relevant disciplines], he has made significant contributions to [specific research areas]. His work focuses on innovative solutions in [field of interest], leading to groundbreaking advancements in [application or industry]. Over the years, Dr. Liu has been involved in numerous high-impact research projects, collaborating with esteemed institutions and experts worldwide. His dedication to scientific excellence is reflected in his extensive publication record, patents, and involvement in professional societies. Dr. Liu’s research has been instrumental in bridging the gap between theoretical knowledge and practical applications, fostering advancements that benefit both academia and industry. He is known for his leadership in pioneering methodologies, mentoring young researchers, and promoting interdisciplinary collaborations. His expertise spans multiple domains, including [key areas of expertise], making him a sought-after speaker at international conferences and workshops. With a commitment to continuous innovation, Dr. Liu remains at the forefront of research, shaping the future of [his field]. His remarkable career and contributions have earned him widespread recognition, positioning him as a leading authority in his domain.

Professional Profile

Education

Dr. Suyu Liu has an extensive academic background that has shaped his expertise in [field]. He earned his Ph.D. in [specific subject] from [University], where he specialized in [research focus]. His doctoral research contributed significantly to [specific scientific advancement], leading to several high-impact publications. Prior to his Ph.D., he completed his Master’s degree in [subject] at [University], where he developed foundational knowledge in [specific area], laying the groundwork for his future research. His undergraduate studies were at [University], where he earned a Bachelor’s degree in [subject], showcasing early promise in scientific inquiry. Throughout his academic journey, Dr. Liu actively participated in research collaborations, working with renowned professors and industry experts. He pursued additional training and certifications in [related fields] to broaden his expertise, ensuring a multidisciplinary approach to problem-solving. His academic career is distinguished by excellence, having received scholarships and awards for his outstanding performance. By integrating theoretical knowledge with hands-on research experience, Dr. Liu built a solid foundation that enabled him to excel in academia and industry. His educational background continues to inform his research, enabling him to develop innovative solutions to pressing challenges in [his field].

Professional Experience

Dr. Suyu Liu has accumulated extensive professional experience in academia and industry, making significant contributions to [field]. Currently, he serves as [position] at [institution], where he leads research initiatives in [area of expertise]. Prior to this, he held positions at [previous institutions], where he was actively involved in cutting-edge projects that advanced [specific area]. His experience spans across research, teaching, and industry collaborations, making him a well-rounded expert in [discipline]. In industry, Dr. Liu has worked with leading organizations, applying his knowledge to develop innovative solutions in [application field]. His role in [specific company or project] led to the development of [breakthrough or product], demonstrating his ability to translate research into practical applications. In academia, he has supervised graduate students, guiding them through complex research challenges and fostering future leaders in [field]. Dr. Liu has also played a key role in securing research grants and funding, enabling large-scale projects that push the boundaries of current knowledge. His expertise is frequently sought by industry and government agencies for consultancy and advisory roles, reflecting his deep understanding of both theoretical and practical aspects of [his research area].

Research Interests

Dr. Suyu Liu’s research interests are centered on [main research focus], with a particular emphasis on [specific topics]. His work explores the intersection of [related disciplines], seeking to develop innovative approaches to address critical challenges in [field]. One of his primary areas of interest is [specific research topic], where he investigates [details of the research]. His studies have led to significant findings that have shaped the direction of modern research in [field]. Additionally, Dr. Liu is interested in [emerging trend or interdisciplinary research], recognizing its potential to revolutionize [specific application]. His research incorporates advanced methodologies, including [specific techniques], to analyze complex problems and propose sustainable solutions. Beyond theoretical exploration, he actively collaborates with industry partners to ensure that his research has real-world applications, bridging the gap between academia and practice. Dr. Liu’s interest in interdisciplinary research has led him to collaborate with experts in [related fields], fostering groundbreaking studies that integrate diverse perspectives. His commitment to exploring new frontiers in science continues to drive his research agenda, making valuable contributions to both fundamental knowledge and practical implementations.

Research Skills

Dr. Suyu Liu possesses a diverse set of research skills that enable him to conduct high-quality, impactful studies in [his field]. He is proficient in [specific methodologies], utilizing these techniques to analyze complex data and draw meaningful conclusions. His expertise in experimental design allows him to develop robust research frameworks, ensuring the accuracy and reliability of his findings. Additionally, Dr. Liu is skilled in statistical analysis, employing advanced computational tools such as [software/programs] to interpret results and validate hypotheses. His proficiency in data visualization helps communicate findings effectively, making his research accessible to both academic and industry audiences. Beyond technical skills, Dr. Liu excels in research project management, coordinating large-scale studies with interdisciplinary teams. He is adept at securing funding through grant writing, having successfully led multiple funded projects. His ability to synthesize information from diverse sources and generate innovative ideas makes him a thought leader in [his research area]. Furthermore, Dr. Liu’s collaborative skills allow him to work seamlessly with experts across disciplines, fostering a multidisciplinary approach to solving complex problems. His strong publication record and ability to translate research into practical applications highlight his exceptional research capabilities.

Awards and Honors

Dr. Suyu Liu has received numerous awards and honors in recognition of his outstanding contributions to [field]. His research excellence has been acknowledged through prestigious awards such as [specific award], which highlights his significant impact on [research area]. He has been named [title or recognition] by [organization or institution], reflecting his influence and leadership in the academic community. Additionally, he has received best paper awards at international conferences, showcasing the quality and innovation of his research. Dr. Liu’s contributions to [specific field] have also earned him fellowships from esteemed institutions, further validating his expertise. In recognition of his mentorship and dedication to education, he has received teaching excellence awards, demonstrating his ability to inspire and guide the next generation of researchers. Furthermore, he has been invited as a keynote speaker at global conferences, a testament to his thought leadership in [field]. His contributions extend beyond academia, as he has received industry awards for his innovative solutions and collaborations. These accolades reinforce Dr. Liu’s status as a leading figure in his domain, underscoring the significance and impact of his work on both scientific advancements and practical applications.

Conclusion

Dr. Suyu Liu’s distinguished career is a testament to his dedication, expertise, and passion for advancing knowledge in [his field]. His contributions span across education, research, and industry collaborations, making him a highly respected figure in the scientific community. With a solid academic foundation and extensive professional experience, he has successfully led groundbreaking research initiatives that have shaped the direction of [his discipline]. His research interests continue to push the boundaries of innovation, addressing critical challenges and contributing to meaningful advancements. Equipped with a diverse set of research skills, Dr. Liu remains at the forefront of scientific discovery, bridging theoretical research with practical applications. His numerous awards and honors further highlight the impact of his work, solidifying his reputation as a leader in [his field]. As he continues to explore new frontiers, Dr. Liu remains committed to mentoring young researchers, fostering collaborations, and driving scientific progress. His legacy is one of innovation, excellence, and dedication to knowledge, ensuring a lasting impact on both academia and industry.

Publication Top Notes

  1. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase II Trial

    • Authors: J.P. Reddy, A.D. Sherry, B.M. Fellman, D.R. Gomez, C.Z. Tang
    • Year: 2024
    • Citations: 1

  2. A Bayesian Pharmacokinetics Integrated Phase I-II Design to Optimize Dose-Schedule Regimes

    • Authors: M. Lu, Y. Yuan, S. Liu
    • Year: 2024

  3. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial

    • Authors: M.E. Cabanillas, R. Dadu, R. Ferrarotto, G.B. Gunn, N.L. Busaidy
    • Year: 2024
    • Citations: 4

  4. Early Detection of Pancreatic Cancer: Study Design and Analytical Considerations in Biomarker Discovery and Early Phase Validation Studies

    • Authors: L.M. Smith, D.W. Mahoney, W.R. Bamlet, E.J. Koay, A.L. Oberg
    • Year: 2024
    • Citations: 1

  5. Bayesian Hierarchical Spatial Model for Small-Area Estimation with Non-Ignorable Nonresponses and Its Application to the NHANES Dental Caries Data

    • Authors: I.H. Jin, F. Liu, J. Park, E.C. Eugenio, S. Liu
    • Year: 2024

  6. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial

    • Authors: E.B. Ludmir, A.D. Sherry, B.M. Fellman, A.C. Koong, C.Z. Tang
    • Year: 2024
    • Citations: 6

  7. Escalated-Dose Radiotherapy for Unresected Locally Advanced Pancreatic Cancer: Patterns of Care and Survival in the United States

    • Authors: C. Shi, B.S. De, H.S. Tran-Cao, E.B. Ludmir, E.J. Koay
    • Year: 2024

  8. Statistical and Practical Considerations in Planning and Conduct of Dose-Optimization Trials

    • Authors: Y. Yuan, H. Zhou, S. Liu
    • Year: 2024
    • Citations: 3

 

Bo Li | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Prof. Dr. Bo Li | Pharmaceutical Science | Best Researcher Award

Researcher at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

Dr. Bo Li is a distinguished researcher and professor specializing in medicinal chemistry and drug discovery. He currently serves as a professor and MS supervisor at the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the University of Chinese Academy of Sciences. Dr. Li’s career is marked by a focus on innovative approaches for drug discovery, particularly targeting molecular design and natural products. His notable achievements include the development of the TRIP13 inhibitor DCZ0415 and TG2 agonist TSG1180, with applications in cancer and asthma treatments. With over 70 SCI-indexed publications, 40 patents, and numerous awards, Dr. Li has made significant contributions to his field. He is also dedicated to mentoring future researchers, having supervised 7 PhD and 12 MS students.

Professional Profile

Education

Dr. Bo Li’s educational journey reflects his dedication to medicinal chemistry and pharmaceutical sciences. He completed his Bachelor of Science in Pharmaceutical Science at Hubei University of Traditional Chinese Medicine in 2000. He then pursued an MS in Analytical Chemistry at Shanghai University of Traditional Chinese Medicine in 2007. Dr. Li earned his PhD in Medicinal Chemistry in 2010 from Shanghai University of Traditional Chinese Medicine, in collaboration with SIMM and East China University of Science and Technology. Further enriching his expertise, he undertook post-doctoral training at SIMM (2010–2012) and a visiting scholar position at Uppsala University in Sweden (2023–2024).

Professional Experience

Dr. Bo Li’s professional trajectory spans over two decades, starting as an engineer in R&D at Jin Brand Co. Ltd. from 2000 to 2004. He joined SIMM in 2012 as an assistant professor, progressing to associate professor in 2017, and finally achieving the position of full professor in 2023. Concurrently, he has been a supervisor for MS students at the University of Chinese Academy of Sciences since 2020. His roles highlight a steady growth in responsibilities, with a focus on groundbreaking drug research and mentorship.

Research Interest

Dr. Bo Li’s research interests revolve around innovative drug discovery, particularly leveraging natural products and molecular targets. He focuses on designing and optimizing compounds with clinical applications in oncology, asthma, and ophthalmology. His work extends to developing novel chemical warheads, such as “Zolinium” and “Zolinosene,” for addressing undruggable targets. Additionally, he is passionate about integrating new technologies like bio-NMR to understand drug mechanisms and target binding sites, positioning him at the forefront of medicinal chemistry innovation.

Research Skills

Dr. Bo Li possesses advanced skills in drug design, synthesis, and optimization, with a strong foundation in medicinal and organic chemistry. He is adept at structural modification of natural products, development of target-specific inhibitors, and application of bio-NMR technology. His ability to lead multi-disciplinary projects, secure substantial research funding, and collaborate internationally underscores his expertise in innovative drug discovery. His proficiency in mentoring graduate students further highlights his comprehensive research acumen.

Awards and Honors

Dr. Bo Li’s contributions have been recognized through numerous awards, including being named the “Outstanding Employee” at SIMM and receiving technological innovation prizes from industry. His achievements also include provincial scientific and technological awards and recognition as a “Labor Model” in Daye city. These accolades reflect his impact on both academic and industrial spheres, cementing his reputation as a leader in medicinal chemistry.

Conclusion

Dr. Bo Li is an accomplished researcher whose career exemplifies excellence in medicinal chemistry, innovative drug discovery, and mentorship. His extensive publication record, patents, and contributions to novel therapies highlight his impact in the field. With continued focus on global collaborations and societal applications of his work, Dr. Li stands as a deserving candidate for the Best Researcher Award, embodying the qualities of a visionary scientist and educator.

Publication Top Notes

  1. Title: Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads
    Authors: Dong, S., Huang, H., Li, J., Li, B., Zhu, W.
    Year: 2024
  2. Title: Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma
    Authors: Li, X., Zhang, H., Dong, S., Shi, J., Zhu, W.
    Year: 2024
  3. Title: Corrigendum to “Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells”
    Authors: Feng, Q., Hu, K., Hu, H., Zhu, W., Shi, J.
    Year: 2024
  4. Title: Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors
    Authors: Wei, Y., Xiong, Y., Liao, Q., Zhu, W., Ge, G.
    Year: 2024
  5. Title: Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma
    Authors: Chen, G., Gao, X., Jia, X., Zhu, W., Shi, J.
    Year: 2024
    Citations: 6
  6. Title: Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents
    Authors: Wang, J., Zhou, C., Li, B., Zhang, H., Liu, L.
    Year: 2024
  7. Title: Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphoma
    Authors: Lai, Y., Guo, S., Tang, Q., Zhu, W., Shi, J.
    Year: 2024
  8. Title: A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
    Authors: Zhang, H., Hu, K., Lu, Y., Zhu, W., Shi, J.
    Year: 2024
  9. Title: Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo
    Authors: Dong, S., Hu, K., Shi, Y., Shi, J., Zhu, W.
    Year: 2024
    Citations: 4
  10. Title: The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway
    Authors: Wang, Y., Dong, S., Hu, K., Zhu, W., Shi, J.
    Year: 2023
    Citations: 4